Pharmaceutical cold chain is expected to become the strongest sub-category in the future development of cold chain logistics. Drug circulation refers to a series of transportation and storage links that drugs go through from the factory to the medical institution or retail pharmacy. In 2018, the drug sales of my country's public hospitals, primary medical institutions, and retail pharmacies were 1.73 trillion yuan, a year-on-year increase of 6.3%. Cold chain circulation is an important part of drug circulation and the most promising business branch in drug circulation.

   Pharmaceutical products that require cold chain transportation include: vaccines, biological products, biological drugs, diagnostic reagents, etc.

   The main varieties of blood products include albumin, intravenous injection, clotting factors, and special immunoglobulins. Due to the relatively mature end market of albumin, the growth rate is slightly slower. Static C, blood coagulation factors, and special immunity products will maintain a relatively high growth rate, and the market space is considerable. The growth rate of the blood products industry is expected to be 5%-10%.

   Several varieties of blood products with a higher growth rate are:

   Jing C: The second-largest blood product variety in the domestic market. Its indications include primary and secondary immunoglobulin deficiency and autoimmune diseases. Due to the high price and insufficient clinical promotion, the selection of disease types and the use of clinical departments in the country were limited before, and there is much room for expansion in the future. The current domestic price is about 60% of the foreign price, and there is a possibility of price increase. In the long run, with further clinical promotion, Jingbing will maintain a good growth rate.

  n Blood coagulation factors: The main species is coagulation factor Ⅷ for the treatment of hemophilia. It is estimated that there are 80,000 hemophilia patients in my country. Due to price reasons, only 40% of patients receive continuous treatment, and only the minimum medication standard is adopted. With the development of the economy and the possibility of further coverage by medical insurance in the future, factor Ⅷ is expected to usher in a rapid release period.

  n Special immunity products: including tetanus immunoglobulin, human rabies vaccine immunoglobulin, hepatitis B vaccine immunoglobulin, etc. These varieties have a small base and are expected to maintain a high growth rate.